StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Inflectra / Remsima (infliximab biosimilar) by Quarter

Inflectra / Remsima (infliximab biosimilar) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Inflectra / Remsima (infliximab biosimilar): $171M in Q2 2026, up 23.0% from a year earlier.

Latest, Q2 2026
171
Period ended Jun 28, 2026
Change on a year earlier
+23.0%
139 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Inflectra | 171 | 139 | 23% | 23% | 165 | 100 | 66% | 5 | 39 | (86%) | (87%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInflectra / Remsima (infliximab biosimilar) — Worldwide revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026171+23.0%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026182+19.0%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025181+42.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025173+37.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025139+43.3%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025153-3.2%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024127+8.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024126+4.1%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 202497+31.1%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024158-11.2%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023117-9.3%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023121-7.6%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 202374-46.0%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023178+31.9%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 2022129-24.6%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 2022131-23.8%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗

Breakdown

What makes up inflectra / Remsima (infliximab biosimilar)

Cite this data

StockData. (2026). Pfizer Inflectra / Remsima (infliximab biosimilar) ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inflectra-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.